首页> 外文期刊>Ocular immunology and inflammation >Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma
【24h】

Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma

机译:根据其与CNS淋巴瘤的关联培养物淋巴瘤的临床特征和治疗结果

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To compare the clinical features and treatment outcomes of different types of vitreoretinal lymphoma (VRL) that presents primarily, secondarily, or concurrently in association with CNS lymphoma.Methods: We retrospectively reviewed the medical records of 53 patients with VRL pathologically confirmed between 2000 and 2014 in two of the largest tertiary hospitals in Korea.Results: The proportions of primary, secondary, and concurrent VRL were 26%, 34%, and 40%, respectively. The primary VRL group had retinal infiltration most frequently (68%) among all groups and presented with the worst visual acuity at diagnosis (P=0.035). The diagnostic delay was significantly shorter in patients with secondary VRL (1.4months; P0.001). Median overall survival was 31months in the entire cohort, and it was shortest in the concurrent VRL/CNS lymphoma group (18months; P=0.007).Conclusions: Ocular presentation and survival times may be different in VRL patients according to the association with CNS involvement.
机译:目的:比较不同类型的玻璃体淋巴瘤(VRL)的临床特征和治疗结果,其主要是与CNS淋巴瘤相关联的。方法:我们回顾性地审查了53例VRL患者的病态,VRL病理到2000年间明显证实在韩国的两个最大的第三张高级医院中的2014年。结果:初级,次要和并发VRL的比例分别为26%,34%和40%。主要VRL组在所有组中最常(68%)具有视网膜渗透,并在诊断时呈现最糟糕的视力(P = 0.035)。二次VRL(1.4months; P <0.001)患者诊断延迟显着较短。中位数总生存率在整个队列中是31个月,并且在同时VRL / CNS淋巴瘤组中最短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号